Your browser doesn't support javascript.
loading
Late-Onset Autosomal Dominant Macular Degeneration Caused by Deletion of the CRX Gene.
Yahya, Samar; Smith, Claire E L; Poulter, James A; McKibbin, Martin; Arno, Gavin; Ellingford, Jamie; Kämpjärvi, Kati; Khan, Muhammad I; Cremers, Frans P M; Hardcastle, Alison J; Castle, Bruce; Steel, David H W; Webster, Andrew R; Black, Graeme C; El-Asrag, Mohammed E; Ali, Manir; Toomes, Carmel; Inglehearn, Chris F.
Afiliação
  • Yahya S; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom; Department of Medical Genetics, School of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
  • Smith CEL; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom.
  • Poulter JA; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom.
  • McKibbin M; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom; Department of Ophthalmology, St. James's University Hospital, Leeds, United Kingdom.
  • Arno G; NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust & UCL Institute of Ophthalmology, London, United Kingdom.
  • Ellingford J; Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, United Kingdom.
  • Kämpjärvi K; Blueprint Genetics Oy, Espoo, Finland.
  • Khan MI; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Cremers FPM; Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Hardcastle AJ; NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust & UCL Institute of Ophthalmology, London, United Kingdom.
  • Castle B; Peninsula Genetics Service, Royal Devon and Exeter Hospitals NHS Trust, Exeter, United Kingdom.
  • Steel DHW; Sunderland Eye Infirmary, Sunderland, United Kingdom; The Bioscience Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Webster AR; NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust & UCL Institute of Ophthalmology, London, United Kingdom.
  • Black GC; Manchester Academic Health Science Centre, School of Biological Sciences, University of Manchester, Manchester, United Kingdom; Manchester Centre for Genomic Medicine, St. Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
  • El-Asrag ME; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom; Department of Zoology, Faculty of Science, Benha University, Benha, Egypt; Institute of Cancer and Genomic Science, University of Birmingham, Birmingham, United Kingdom.
  • Ali M; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom.
  • Toomes C; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom.
  • Inglehearn CF; Leeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, United Kingdom. Electronic address: c.inglehearn@leeds.ac.uk.
Ophthalmology ; 130(1): 68-76, 2023 01.
Article em En | MEDLINE | ID: mdl-35934205
PURPOSE: To characterize the phenotype observed in a case series with macular disease and determine the cause. DESIGN: Multicenter case series. PARTICIPANTS: Six families (7 patients) with sporadic or multiplex macular disease with onset at 20 to 78 years, and 1 patient with age-related macular degeneration. METHODS: Patients underwent ophthalmic examination; exome, genome, or targeted sequencing; and/or polymerase chain reaction (PCR) amplification of the breakpoint, followed by cloning and Sanger sequencing or direct Sanger sequencing. MAIN OUTCOME MEASURES: Clinical phenotypes, genomic findings, and a hypothesis explaining the mechanism underlying disease in these patients. RESULTS: All 8 cases carried the same deletion encompassing the genes TPRX1, CRX, and SULT2A1, which was absent from 382 control individuals screened by breakpoint PCR and 13 096 Clinical Genetics patients with a range of other inherited conditions screened by array comparative genomic hybridization. Microsatellite genotypes showed that these 7 families are not closely related, but genotypes immediately adjacent to the deletion breakpoints suggest they may share a distant common ancestor. CONCLUSIONS: Previous studies had found that carriers for a single defective CRX allele that was predicted to produce no functional CRX protein had a normal ocular phenotype. Here, we show that CRX whole-gene deletion in fact does cause a dominant late-onset macular disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Degeneração Macular Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Degeneração Macular Idioma: En Ano de publicação: 2023 Tipo de documento: Article